Search

Your search keyword '"Jurczyszyn, Artur"' showing total 13 results
Start Over Author "Jurczyszyn, Artur" Journal leukemia & lymphoma
13 results on '"Jurczyszyn, Artur"'

1. Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes

Author

Garderet, Laurent, primary, Al Hariri, Mohammad, additional, Wasielica-Poslednik, Joanna, additional, Munder, Markus, additional, Kormányos, Kitti, additional, Pena, Camila, additional, Gozzetti, Alessandro, additional, Zhou, Xiang, additional, Waszczuk-Gajda, Anna, additional, Rosinol, Laura, additional, Mikala, Gabor, additional, Krzystanski, Mateusz, additional, Lisch, Walter, additional, Vesole, David, additional, Szentmáry, Nóra, additional, and Jurczyszyn, Artur, additional

Published
2021
Full Text
View/download PDF

2. Primary refractory multiple myeloma: a real-world experience with 85 cases

Author

Jurczyszyn, Artur, primary, Waszczuk-Gajda, Anna, additional, Castillo, Jorge J., additional, Krawczyk, Katarzyna, additional, Stork, Martin, additional, Pour, Ludek, additional, Usnarska-Zubkiewicz, Lidia, additional, Potoczek, Stanisław, additional, Hus, Iwona, additional, Davila Valls, Julio, additional, Hari, Parameswaran, additional, Chhabra, Saurabh, additional, Gentile, Massimo, additional, Mikala, Gabor, additional, Varga, Gergely, additional, Chim, Chor Sang, additional, Fiala, Mark, additional, Vij, Ravi, additional, Schutz, Natalia, additional, Rodzaj, Marek, additional, Porowska, Agnieszka, additional, Vesole, David H., additional, Druzd-Sitek, Agnieszka, additional, Walewski, Jan, additional, and Nooka, Ajay K., additional

Published
2020
Full Text
View/download PDF

3. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Author

Goldman-Mazur, Sarah, primary, Jurczyszyn, Artur, additional, Castillo, Jorge J., additional, Waszczuk-Gajda, Anna, additional, Grząśko, Norbert, additional, Radocha, Jakub, additional, Bittrich, Max, additional, Kortüm, Klaus Martin, additional, Gozzetti, Alessandro, additional, Usnarska-Zubkiewicz, Lidia, additional, Valls, Julio D., additional, Jayabalan, David S., additional, Niesvizky, Ruben, additional, Kelman, Julia, additional, Coriu, Daniel, additional, Rosiñol, Laura, additional, Szukalski, Łukasz, additional, González-Calle, Veronica, additional, Mateos, María-Victoria, additional, Jamroziak, Krzysztof, additional, Hus, Iwona, additional, Avivi, Irit, additional, Cohen, Yael, additional, Mazur, Piotr, additional, Suska, Anna, additional, Chappell, Aimee, additional, Madduri, Deepu, additional, Chhabra, Saurabh, additional, Kleman, Ariel, additional, Hari, Parameswaran, additional, Delforge, Michel, additional, Robak, Paweł, additional, Gentile, Massimo, additional, Kozłowska, Izabela, additional, Goldberg, Stuart L., additional, Czepiel, Jacek, additional, Długosz-Danecka, Monika, additional, Silbermann, Rebecca, additional, Olszewski, Adam J., additional, Barth, Peter, additional, Mikala, Gabor, additional, Chim, Chor S., additional, and Vesole, David H., additional

Published
2020
Full Text
View/download PDF

4. Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes.

Author

Garderet, Laurent, Al Hariri, Mohammad, Wasielica-Poslednik, Joanna, Munder, Markus, Kormányos, Kitti, Pena, Camila, Gozzetti, Alessandro, Zhou, Xiang, Waszczuk-Gajda, Anna, Rosinol, Laura, Mikala, Gabor, Krzystanski, Mateusz, Lisch, Walter, Vesole, David, Szentmáry, Nóra, and Jurczyszyn, Artur

Subjects
MONOCLONAL gammopathies, PLASMA cell diseases, TREATMENT effectiveness, STEM cell transplantation, MULTIPLE myeloma, CORNEA
Abstract

Monoclonal gammopathy of ocular significance (MGOS) is a rare subset of monoclonal gammopathy of clinical significance occurring secondary to plasma cell disorders and causing ocular manifestations. We identified 23 patients with paraproteinemic keratopathy (PPK) in the setting of monoclonal gammopathy of unknown significance (MGUS, 10), smoldering multiple myeloma (SMM, 3) or multiple myeloma (MM, 10). Many of these patients with PPK (11/23) presented decreased vision. All patients with MM and 40% of those with other diagnoses such as SMM and MGUS received systemic therapy with or without autologous stem cell transplantation. Four eyes of four patients were treated by penetrating keratoplasty. In most cases, neither ocular nor hematologic treatment afforded a durable improvement in the visual acuity (recurrence after a median of 11 months), despite initial responses. Further studies will be required to determine the optimal strategy to treat and prevent the relapse of ocular symptoms in patients with PPK. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

5. Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium

Author

Iskierka-Jażdżewska, Elżbieta, primary, Canzian, Federico, additional, Stępień, Anna, additional, Martino, Alessandro, additional, Campa, Daniele, additional, Stein, Angelica, additional, Krawczyk-Kuliś, Małgorzata, additional, Rybicka-Ramos, Malwina, additional, Kyrcz-Krzemień, Sławomira, additional, Butrym, Aleksandra, additional, Mazur, Grzegorz, additional, Jurczyszyn, Artur, additional, Zawirska, Daria, additional, Grząśko, Norbert, additional, Tomczak, Waldemar, additional, Subocz, Edyta, additional, Wątek, Marzena, additional, Pasiarski, Marcin, additional, Rymko, Marcin, additional, Całbecka, Małgorzata, additional, Druzd-Sitek, Agnieszka, additional, Walewski, Jan, additional, Kruszewski, Marcin, additional, Raźny, Małgorzata, additional, Zaucha, Jan Maciej, additional, Dudziński, Marek, additional, Gaj, Paweł, additional, Robak, Tadeusz, additional, Warzocha, Krzysztof, additional, and Jamroziak, Krzysztof, additional

Published
2019
Full Text
View/download PDF

6. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

Author

Campa, Daniele, primary, Martino, Alessandro, additional, Macauda, Angelica, additional, Dudziński, Marek, additional, Suska, Anna, additional, Druzd-Sitek, Agnieszka, additional, Raab, Marc-Steffen, additional, Moreno, Victor, additional, Huhn, Stefanie, additional, Butrym, Aleksandra, additional, Sainz, Juan, additional, Szombath, Gergely, additional, Rymko, Marcin, additional, Marques, Herlander, additional, Lesueur, Fabienne, additional, Vangsted, Annette Juul, additional, Vogel, Ulla, additional, Kruszewski, Marcin, additional, Subocz, Edyta, additional, Buda, Gabriele, additional, Iskierka-Jażdżewska, Elżbieta, additional, Ríos, Rafael, additional, Merz, Maximilian, additional, Schöttker, Ben, additional, Mazur, Grzegorz, additional, Perrial, Emeline, additional, Martinez-Lopez, Joaquin, additional, Butterbach, Katja, additional, García Sanz, Ramón, additional, Goldschmidt, Hartmut, additional, Brenner, Hermann, additional, Jamroziak, Krzysztof, additional, Reis, Rui Manuel, additional, Kadar, Katalin, additional, Dumontet, Charles, additional, Wątek, Marzena, additional, Haastrup, Eva Kannik, additional, Helbig, Grzegorz, additional, Jurczyszyn, Artur, additional, Jerez, Andrés, additional, Varkonyi, Judit, additional, Barington, Torben, additional, Grzasko, Norbert, additional, Zaucha, Jan Maciej, additional, Andersen, Vibeke, additional, Zawirska, Daria, additional, and Canzian, Federico, additional

Published
2019
Full Text
View/download PDF

7. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

Author

Jurczyszyn, Artur, primary, Davila, Julio, additional, Kortüm, K. Martin, additional, Jayabalan, David S., additional, Vij, Ravi, additional, Fiala, Mark, additional, Milunovic, Vibor, additional, Chim, C.S., additional, Wiśniewska-Piąty, Katarzyna, additional, Waszczuk-Gajda, Anna, additional, Crusoe, Edvan, additional, Hajek, Roman, additional, Robak, Paweł, additional, Raźny, Małgorzata, additional, Zawirska, Daria, additional, Bittrich, Max, additional, Nahi, Hareth, additional, Liu, Jieqi, additional, Castillo, Jorge J., additional, and Vesole, David H., additional

Published
2018
Full Text
View/download PDF

8. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Author

Jurczyszyn, Artur, primary, Castillo, Jorge J., additional, Avivi, Irit, additional, Czepiel, Jacek, additional, Davila, Julio, additional, Vij, Ravi, additional, Fiala, Mark A., additional, Gozzetti, Alessandro, additional, Grząśko, Norbert, additional, Milunovic, Vibor, additional, Hus, Iwona, additional, Mądry, Krzysztof, additional, Waszczuk-Gajda, Anna, additional, Usnarska-Zubkiewicz, Lidia, additional, Dębski, Jakub, additional, Atilla, Erden, additional, Beksac, Meral, additional, Mele, Giuseppe, additional, Sawicki, Waldemar, additional, Jayabalan, David, additional, Charliński, Grzegorz, additional, Gyula Szabo, Agoston, additional, Hajek, Roman, additional, Delforge, Michel, additional, Kopacz, Agnieszka, additional, Fantl, Dorotea, additional, Waage, Anders, additional, Crusoe, Edvan, additional, Hungria, Vania, additional, Richardson, Paul, additional, Laubach, Jacob, additional, Guerrero-Garcia, Thomas, additional, Liu, Jieqi, additional, and Vesole, David H., additional

Published
2018
Full Text
View/download PDF

9. Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium.

Author

Iskierka-Jażdżewska, Elżbieta, Canzian, Federico, Stępień, Anna, Martino, Alessandro, Campa, Daniele, Stein, Angelica, Krawczyk-Kuliś, Małgorzata, Rybicka-Ramos, Malwina, Kyrcz-Krzemień, Sławomira, Butrym, Aleksandra, Mazur, Grzegorz, Jurczyszyn, Artur, Zawirska, Daria, Grząśko, Norbert, Tomczak, Waldemar, Subocz, Edyta, Wątek, Marzena, Pasiarski, Marcin, Rymko, Marcin, and Całbecka, Małgorzata

Subjects
MULTIPLE myeloma, PROGRESSION-free survival, GENETIC polymorphisms, SINGLE nucleotide polymorphisms, CONSORTIA, CD38 antigen
Abstract

Cereblon (CRBN) is crucial for antiproliferative and immunomodulatory properties of immunomodulatory drugs. The objective of this study was to verify whether germline single nucleotide polymorphisms (SNPs) in the CRBN gene may influence response to lenalidomide in multiple myeloma (MM). Fourteen tagging SNPs covering the genetic variability in the CRBN gene region were genotyped in 167 Polish patients with refractory/relapsed MM treated with lenalidomide-based regimens. We found that carriers of minor alleles of two studied CRBN SNPs rs1714327G > C (OR = 0.26; 95% CI = 0.1–0.67; p =.0055, Bonferroni corrected p =.033) and rs1705814T > C (OR = 0.22; 95% CI = 0.07–0.65; p =.0063, Bonferroni corrected p =.037) were significantly associated with lower probability of achievement at least partial remission while treated with lenalidomide-based regimens, using the dominant inheritance model. Moreover, one of these SNPs, namely rs1705814T > C, was correlated with shorter progression-free survival (HR = 2.49; 95%CI = 1.31–4.74, p =.0054, Bonferroni corrected p =.033). It is suggested that selected germline CRBN allelic variants (rs1714327G > C and rs1705814T > C) affect lenalidomide efficacy in patients with relapsed/refractory MM. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

10. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group

Author

Grzasko, Norbert, primary, Hajek, Roman, additional, Hus, Marek, additional, Chocholska, Sylwia, additional, Morawska, Marta, additional, Giannopoulos, Krzysztof, additional, Czarnocki, Krzysztof, additional, Druzd-Sitek, Agnieszka, additional, Pienkowska-Grela, Barbara, additional, Rygier, Jolanta, additional, Usnarska-Zubkiewicz, Lidia, additional, Dytfeld, Dominik, additional, Kubicki, Tadeusz, additional, Jurczyszyn, Artur, additional, Korpysz, Maciej, additional, and Dmoszynska, Anna, additional

Published
2017
Full Text
View/download PDF

11. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.

Author

Jurczyszyn, Artur, Crusoe, Edvan, Hajek, Roman, Robak, Paweł, Raźny, Małgorzata, Zawirska, Daria, Nahi, Hareth, Liu, Jieqi, Castillo, Jorge J., Vesole, David H., Davila, Julio, Kortüm, K. Martin, Bittrich, Max, Jayabalan, David S., Vij, Ravi, Fiala, Mark, Milunovic, Vibor, Chim, C.S., Wiśniewska-Piąty, Katarzyna, and Waszczuk-Gajda, Anna

Subjects
*MULTIPLE myeloma, *STEM cell transplantation, *LACTATE dehydrogenase
Abstract

A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8-30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53-222), with 5-year OS rate of 77% (95% CI: 61.0-87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

12. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.

Author

Jurczyszyn, Artur, Castillo, Jorge J., Avivi, Irit, Czepiel, Jacek, Davila, Julio, Vij, Ravi, Fiala, Mark A., Gozzetti, Alessandro, Grząśko, Norbert, Milunovic, Vibor, Hus, Iwona, Mądry, Krzysztof, Waszczuk-Gajda, Anna, Usnarska-Zubkiewicz, Lidia, Dębski, Jakub, Atilla, Erden, Beksac, Meral, Mele, Giuseppe, Sawicki, Waldemar, and Jayabalan, David

Subjects
*PLASMA cells
Abstract

This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 109/L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p = .0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

13. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients

Author

Jurczyszyn, Artur, primary, Olszewska-Szopa, Magdalena, additional, Hungria, Vania, additional, Crusoe, Edvan, additional, Pika, Tomas, additional, Delforge, Michel, additional, Leleu, Xavier, additional, Rasche, Leo, additional, Nooka, Ajay K., additional, Druzd-Sitek, Agnieszka, additional, Walewski, Jan, additional, Davila, Julio, additional, Caers, Jo, additional, Maisnar, Vladimir, additional, Gertz, Morie, additional, Gentile, Massimo, additional, Fantl, Dorotea, additional, Mele, Giuseppe, additional, Vesole, David H., additional, Yee, Andrew J., additional, Shustik, Chaim, additional, Lentzsch, Suzanne, additional, Zweegman, Sonja, additional, Gozzetti, Alessandro, additional, Skotnicki, Aleksander B., additional, and Castillo, Jorge J., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results